Missed GME or NVDA? Donโt Miss the Next One.โ
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
GLUE Stock Forecast 2025-2026
$3.87
Current Price
$227.59M
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to GLUE Price Targets
+416.8%
To High Target of $20.00
+326.4%
To Median Target of $16.50
+158.4%
To Low Target of $10.00
GLUE Price Momentum
-5.4%
1 Week Change
-12.2%
1 Month Change
-25.9%
1 Year Change
-44.2%
Year-to-Date Change
-68.8%
From 52W High of $12.40
+20.6%
From 52W Low of $3.21
๐ MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Monte Rosa (GLUE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on GLUE and similar high-potential opportunities.
Latest GLUE Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, GLUE has a bullish consensus with a median price target of $16.50 (ranging from $10.00 to $20.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $3.87, the median forecast implies a 326.4% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kelly Shi at Jefferies, projecting a 416.8% upside. Conversely, the most conservative target is provided by Derek Archila at Wells Fargo, suggesting a 158.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GLUE Analyst Ratings
8
Buy
1
Hold
0
Sell
GLUE Price Target Range
Low
$10.00
Average
$16.50
High
$20.00
Current: $3.87
Latest GLUE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GLUE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $10.00 |
| Mar 21, 2025 | Wedbush | Robert Driscoll | Outperform | Maintains | $17.00 |
| Mar 12, 2025 | LifeSci Capital | Outperform | Initiates | $19.00 | |
| Dec 19, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $11.00 |
| Sep 12, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $11.00 |
| Aug 12, 2024 | Wells Fargo | Derek Archila | Overweight | Maintains | $17.00 |
| Jun 28, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $16.00 |
| May 22, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $11.00 |
| Feb 15, 2024 | Wedbush | Robert Driscoll | Outperform | Initiates | $11.00 |
| Oct 19, 2023 | JP Morgan | Eric Joseph | Overweight | Maintains | $11.00 |
| Aug 11, 2023 | Credit Suisse | Richard Law | Neutral | Reiterates | $11.00 |
| May 12, 2023 | Credit Suisse | Richard Law | Neutral | Reiterates | $11.00 |
| Mar 17, 2023 | Credit Suisse | Richard Law | Neutral | Maintains | $11.00 |
| Jan 3, 2023 | Wells Fargo | Derek Archila | Overweight | Upgrade | $19.00 |
| Oct 13, 2022 | UBS | Eliana Merle | Buy | Initiates | $22.00 |
| Aug 22, 2022 | Credit Suisse | Neutral | Initiates | $0.00 | |
| Aug 15, 2022 | Jefferies | Kelly Shi | Buy | Initiates | $20.00 |
| May 12, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $21.00 |
| Apr 28, 2022 | Credit Suisse | Neutral | Initiates | $0.00 | |
| Feb 10, 2022 | Wells Fargo | Equal-Weight | Initiates | $0.00 |
Monte Rosa Therapeutics Inc. (GLUE) Competitors
The following stocks are similar to Monte Rosa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Monte Rosa Therapeutics Inc. (GLUE) Financial Data
Monte Rosa Therapeutics Inc. has a market capitalization of $227.59M with a P/E ratio of 30.8x. The company generates $159.49M in trailing twelve-month revenue with a 3.9% profit margin.
Revenue growth is +7,882.0% quarter-over-quarter, while maintaining an operating margin of +51.9% and return on equity of +2.9%.
Valuation Metrics
Market Cap
$227.59M
Enterprise Value
$-56,623,664
P/E Ratio
30.8x
PEG Ratio
-2.5x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+7,882.0%
Gross Margin
N/A
Operating Margin
+51.9%
Net Margin
+3.9%
EPS Growth
+7,882.0%
Financial Health
Cash/Price Ratio
+137.0%
Current Ratio
5.6x
Debt/Equity
15.2x
ROE
+2.9%
ROA
-0.4%
๐ฐ DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Monte Rosa Therapeutics Inc. (GLUE) Business Model
About Monte Rosa Therapeutics Inc.
What They Do
Develops innovative therapies through protein degradation.
Business Model
Monte Rosa Therapeutics generates revenue by developing small molecules that selectively degrade disease-relevant proteins, particularly in oncology. Their unique 'molecular glue' approach allows them to target traditionally 'undruggable' proteins, addressing significant unmet medical needs and expanding their potential market.
Additional Information
Headquartered in Cambridge, Massachusetts, the company utilizes expertise from chemical biology, structural biology, and computational chemistry, positioning itself as a leader in biotechnology and drug discovery. As the demand for new cancer treatments rises, Monte Rosa Therapeutics aims to contribute significantly to healthcare advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
142
CEO
Dr. Markus Warmuth M.D.
Country
United States
IPO Year
2021
Website
www.monterosatx.comMonte Rosa Therapeutics Inc. (GLUE) Latest News & Analysis
Latest News
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
8 days ago
Quick Summary
Monte Rosa Therapeutics is advancing multiple Phase 2 studies for MRT-6160 and MRT-2359, with promising data in cancer. MRT-8102 targets IL-1ฮฒ, IND filing set for H1 2025. Strong cash position supports operations until 2028.
Why It Matters
Advancements in Monte Rosa's clinical programs and strong cash position suggest potential for new treatments and sustained operational funding, enhancing investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Monte Rosa Therapeutics (GLUE) reported Q3 earnings of $0.57 per share, surpassing estimates of a $0.24 loss and improving from a loss of $0.53 per share a year prior.
Why It Matters
Monte Rosa Therapeutics significantly outperformed earnings expectations, signaling potential growth and improving financial health, which could boost investor confidence and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Monte Rosa Therapeutics' MRT-51443, a CDK2 molecular glue degrader, showed superior tumor regression in preclinical models of HR-positive/HER2-negative breast cancer compared to standard treatments.
Why It Matters
Positive preclinical results for Monte Rosa's MRT-51443 indicate potential for improved breast cancer treatment, suggesting a competitive edge in the biotech market and possible future revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Monte Rosa Therapeutics (NASDAQ:GLUE) will hold a Q4 2024 results conference call on March 20, 2025, at 8:00 AM ET to discuss pipeline updates and clinical results.
Why It Matters
The conference call will provide insights on Monte Rosa's pipeline and clinical results, critical for assessing the company's growth potential and investment viability.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Monte Rosa Therapeutics reported promising Phase 1 results for MRT-6160 and MRT-2359 in immune-mediated diseases and prostate cancer. MRT-8102 is set for IND filing in H1 2025. Strong cash reserves are projected to fund operations through 2028.
Why It Matters
Positive clinical results from Monte Rosa Therapeutics could lead to significant advancements in cancer treatment and immune-mediated diseases, influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Monte Rosa Therapeutics (GLUE) reported Q3 earnings of $0.23 per share, surpassing the Zacks estimate of a $0.37 loss, improving from a loss of $0.58 per share a year earlier.
Why It Matters
Monte Rosa Therapeutics' earnings beat expectations, indicating strong performance and potential growth, which can positively influence investor confidence and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About GLUE Stock
What is Monte Rosa Therapeutics Inc.'s (GLUE) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Monte Rosa Therapeutics Inc. (GLUE) has a median price target of $16.50. The highest price target is $20.00 and the lowest is $10.00.
Is GLUE stock a good investment in 2025?
According to current analyst ratings, GLUE has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GLUE stock?
Wall Street analysts predict GLUE stock could reach $16.50 in the next 12 months. This represents a 326.4% increase from the current price of $3.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Monte Rosa Therapeutics Inc.'s business model?
Monte Rosa Therapeutics generates revenue by developing small molecules that selectively degrade disease-relevant proteins, particularly in oncology. Their unique 'molecular glue' approach allows them to target traditionally 'undruggable' proteins, addressing significant unmet medical needs and expanding their potential market.
What is the highest forecasted price for GLUE Monte Rosa Therapeutics Inc.?
The highest price target for GLUE is $20.00 from Kelly Shi at Jefferies, which represents a 416.8% increase from the current price of $3.87.
What is the lowest forecasted price for GLUE Monte Rosa Therapeutics Inc.?
The lowest price target for GLUE is $10.00 from Derek Archila at Wells Fargo, which represents a 158.4% increase from the current price of $3.87.
What is the overall GLUE consensus from analysts for Monte Rosa Therapeutics Inc.?
The overall analyst consensus for GLUE is bullish. Out of 8 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $16.50.
How accurate are GLUE stock price projections?
Stock price projections, including those for Monte Rosa Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 5:37 AM UTC